DIUCARDIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Diucardin, and when can generic versions of Diucardin launch?
Diucardin is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in DIUCARDIN is hydroflumethiazide. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide profile page.
Summary for DIUCARDIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Patent Applications: | 3,806 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | DIUCARDIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for DIUCARDIN
US Patents and Regulatory Information for DIUCARDIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | DIUCARDIN | hydroflumethiazide | TABLET;ORAL | 083383-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
